Lycopene-whey complex (bioavailable lycopene) and risk of atherosclerotic plaques Scientific substantiation of a health claim related to Lycopene-whey complex (bioavailable lycopene) and reduction of the risk of atherosclerotic plaques pursuant to Article 14 of Regulation (EC) No 1924/2006 [1]

lycopene, lipoprotein oxidisability, atherosclerotic plaques, atherosclerosis, health claim
First published in the EFSA Journal
3 August 2009
2 July 2009
Scientific Opinion

No abstract available

Panel members at the time of adoption
Jean-Louis Bresson, Albert Flynn, Marina Heinonen, Karin Hulshof, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Hildegard Przyrembel, Seppo Salminen, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Henk van den Berg, Hendrik van Loveren and Hans Verhagen.
Panel on Dietetic Products, Nutrition and Allergies
Question Number